Polyclonal antibody Pylorimune-G

Drug Profile

Polyclonal antibody Pylorimune-G

Alternative Names: Pylorimune-G

Latest Information Update: 01 Apr 2003

Price : $50

At a glance

  • Originator GalaGen
  • Developer Chiron Corporation; GalaGen
  • Class Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Helicobacter infections

Most Recent Events

  • 29 Mar 2000 No-Development-Reported for Helicobacter infections in USA (PO)
  • 02 Dec 1998 Discontinued - Preclinical for Helicobacter infections in USA (PO)
  • 03 Dec 1997 Preclinical development for Helicobacter infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top